TOPAMAX SPRINKLE
TOPIRAMATE
Approval overview TOPAMAX SPRINKLE is listed in Drugs@FDA under application 020844 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient TOPIRAMATE Form and strength CAPSULE;ORAL - 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor JANSSEN PHARMS Submission history Latest submission status date: 2026-03-06 00:00:00.
Structured Monograph
Clinical summary
Approval overview TOPAMAX SPRINKLE is listed in Drugs@FDA under application 020844 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient TOPIRAMATE Form and strength CAPSULE;ORAL - 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor JANSSEN PHARMS Submission history Latest submission status date: 2026-03-06 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.